BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1700167)

  • 1. [A clinical study of complements as a marker of a hepatocellular carcinoma].
    Takezaki E; Murakami S; Nishibayashi H; Kagawa K; Ohmori H
    Gan No Rinsho; 1990 Oct; 36(12):2119-22. PubMed ID: 1700167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biological significance of serum complements C3 and C4 in HCV-related chronic liver diseases and hepatocellular carcinoma.
    Ali OS; Abo-Shadi MA; Hammad LN
    Egypt J Immunol; 2005; 12(2):91-9. PubMed ID: 17977214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two patients with liver cirrhosis who presented with alpha-fetoprotein values diagnostic of hepatocarcinoma but without evidence of neoplasms].
    Cristani A; Borghi A; Cioni G; Vignoli A; Ventura E
    Recenti Prog Med; 1992 May; 83(5):286-7. PubMed ID: 1279760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
    Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
    Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
    Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
    Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complements as new diagnostic tools of hepatocellular carcinoma in cirrhotic patients.
    Chang WY; Chuang WL
    Cancer; 1988 Jul; 62(2):227-32. PubMed ID: 2454720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of alpha-fetoprotein-L3 using agglutinin-coupled spin column to be used in diagnosis of hepatocellular carcinoma].
    Sun GZ; Zhao XY; Li JH; Zhao GQ; Wang SX; Kong SL
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1986-8. PubMed ID: 19062741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.
    Marrero JA; Romano PR; Nikolaeva O; Steel L; Mehta A; Fimmel CJ; Comunale MA; D'Amelio A; Lok AS; Block TM
    J Hepatol; 2005 Dec; 43(6):1007-12. PubMed ID: 16137783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
    Song KS; Lee A; Choi JR; Kwon OH
    Thromb Haemost; 1995 Sep; 74(3):864-7. PubMed ID: 8571313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.